Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for Self-injuries in Severe Neurodevelopmental Disorders
NCT07564245Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2026
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cannabidiol in Self-injurious behavior, sponsored by Assistance publique - Hôpitaux de Paris. Planned start May 2026; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
Self-injurious behavior
Beyond the preview
Go deeper on NCT07564245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07564245.